[Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices].
Antiretroviral and prophylactic therapy given to HIV-infected patients attending hospital (DMI 2 data base) was analyzed according to TCD4+ cell count; 19,020 patients were included in the study. Under 200 TCD4+/mm3, more than 80% of the patients received antiviral therapy, most often AZT (45.3%) or ddI (27.2%). Combined treatment was quite low, less than 8%. Although above 500 TCD4+/mm3, 11.6% of patients received AZT, this study showed that antiretroviral therapy followed French recommendations. This was not the case for prophylaxis: a large proportion of patients under 200 TCD4+/mm3 did not received pentamidine aerosol, or cotrimoxazole, or dapsone.
Bourdillon
F
F
Mission Sida, Ministère des Affaires Sociales, Paris.
André
E
E
Nadal
J M
JM
Delfraissy
J F
JF
Bez
G
G
D000890:Anti-Infective Agents; D000998:Antiviral Agents; D018791:CD4 Lymphocyte Count; D003622:Dapsone; D016049:Didanosine; D004363:Drug Utilization; D005602:France; D015658:HIV Infections / Q000188:drug therapy*; D006751:Hospital Information Systems; D006753:Hospital Records; D006801:Humans; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D016047:Zalcitabine; D015215:Zidovudine
D000890:Anti-Infective Agents; D000998:Antiviral Agents; D015215:Zidovudine; D010419:Pentamidine; D016047:Zalcitabine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D016049:Didanosine
Les prescriptions des antirétroviraux et des médicaments prophylactiques dans la pathologie VIH: la réalité des pratiques médicales.